Sandbox vidit2: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 16: | Line 16: | ||
{{familytree | | | | | | | | G01 | | | | | G02 | | | | | G03 |G01=General management|G02=Etiology specific management|G03=Complication specific management}} | {{familytree | | | | | | | | G01 | | | | | G02 | | | | | G03 |G01=General management|G02=Etiology specific management|G03=Complication specific management}} | ||
{{familytree/end}} | {{familytree/end}} | ||
===General Management=== | ===General Management=== | ||
Line 27: | Line 28: | ||
{{familytree | C01 | | | C02 | | | C03 | | | C04 | | | C05 | | | C06 | | | C07 | | | C08 | | | C09 | | | C10 | | | C11 |C01=*Monitor ICP, CPP & cerebral oxygenation<BR>*Elevate head end to 30°<BR>*Monitor fluid status<BR>*3% NS<BR>*Avoid NGT and suction|C02=*Platelet count & coagulation profile (12th hourly)<BR>*Inj. Vit. K<BR>*Cryoprecipitate|C03=*Discontinue medications<BR>*Avoid nephrotoxic & hepatotoxic drugs|C04=*Ranitidine|C05=*Monitor CVP w/ central venous catheter|C06=*Frequent monitoring of mental status|C07=*CBC (12th hourly)<BR>*CXR; sputum, blood & urine cultures (daily)<BR>*Cefotaxime, meropenem, fluconazole or vancomycin|C08=*Serum BCH, ABG, lactate (12th hourly)<BR>*Serum glucose (2nd hourly)|C09=*NAC (i.v × 2d then P.O.)|C10=*Eternal feeding<BR>*Parental feeding|C11=*Urinary I/O}} | {{familytree | C01 | | | C02 | | | C03 | | | C04 | | | C05 | | | C06 | | | C07 | | | C08 | | | C09 | | | C10 | | | C11 |C01=*Monitor ICP, CPP & cerebral oxygenation<BR>*Elevate head end to 30°<BR>*Monitor fluid status<BR>*3% NS<BR>*Avoid NGT and suction|C02=*Platelet count & coagulation profile (12th hourly)<BR>*Inj. Vit. K<BR>*Cryoprecipitate|C03=*Discontinue medications<BR>*Avoid nephrotoxic & hepatotoxic drugs|C04=*Ranitidine|C05=*Monitor CVP w/ central venous catheter|C06=*Frequent monitoring of mental status|C07=*CBC (12th hourly)<BR>*CXR; sputum, blood & urine cultures (daily)<BR>*Cefotaxime, meropenem, fluconazole or vancomycin|C08=*Serum BCH, ABG, lactate (12th hourly)<BR>*Serum glucose (2nd hourly)|C09=*NAC (i.v × 2d then P.O.)|C10=*Eternal feeding<BR>*Parental feeding|C11=*Urinary I/O}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Line 42: | Line 42: | ||
{{familytree | D01 | | | D02 | | | D03 | | | D04 | | | D05 | | | D06 | | | D07 | | | D08 | | | D09 | | | D10 | | | D11 |D01=Activated charcoal<BR>NAC|D02=Deliver immediately|D03=Manage the cause of ischemia|D04=Prednisolone<BR>Transplantation|D05=Transplantation|D06=Discontinue all possible medications except essential drugs|D07=Supportive Rx|D08=Activated charcoal & gastric lavage<BR>Penicillin G or Silibinin<BR>Fluid resuscitation|D09=Supportive Rx<BR>Lamivudine or adefovir<BR>Acyclovir|D10=Dialysis or hemofiltration or plasmapheresis or plasma exchange<BR>Transplantation|D11=Incomplete drug or toxin intake H/O<BR>Transjugular biopsy to R/O mailgnancy, Wilson's disease, autoimmune hepatitis or viral hepatitis}} | {{familytree | D01 | | | D02 | | | D03 | | | D04 | | | D05 | | | D06 | | | D07 | | | D08 | | | D09 | | | D10 | | | D11 |D01=Activated charcoal<BR>NAC|D02=Deliver immediately|D03=Manage the cause of ischemia|D04=Prednisolone<BR>Transplantation|D05=Transplantation|D06=Discontinue all possible medications except essential drugs|D07=Supportive Rx|D08=Activated charcoal & gastric lavage<BR>Penicillin G or Silibinin<BR>Fluid resuscitation|D09=Supportive Rx<BR>Lamivudine or adefovir<BR>Acyclovir|D10=Dialysis or hemofiltration or plasmapheresis or plasma exchange<BR>Transplantation|D11=Incomplete drug or toxin intake H/O<BR>Transjugular biopsy to R/O mailgnancy, Wilson's disease, autoimmune hepatitis or viral hepatitis}} | ||
{{familytree/end}} | {{familytree/end}} | ||
===Complication Specific Management=== | ===Complication Specific Management=== |
Revision as of 19:35, 9 December 2013
Management
Altered mental status & PT prolongation by 4-6 sec or INR ≥1.5 presenting w/ nonspecific abdominal Sx w/o preexisting chronic liver disease, cirrhosis & any illness of <26 wks duration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acute liver failure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mandatory hospital admission | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
w/o altered mental status, significant coagulopathy & abnormal LFT | w/ altered mental status | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High dependency ward admission | Worsening mental status | ICU admission | w/ or progression to grade I/II hepatic encephalopathy | Transfer to transplant center | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initial evaluation: Detailed H/o and PE Labs: CBC, PT/INR, serum BCH, ABG, ammonia, acetaminophen & tox screen for other drugs/toxins, viral serology (A-E), autoimmune markers, amylase, lipase, bilirubin:alkaline phosphatase, blood grouping & typing, HIV status | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General management | Etiology specific management | Complication specific management | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Management
Continuous monitoring under quite environment w/ preventive treatment strategies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cerebral edema & increased ICP | Coagulopathy | Drugs | GI bleeding | Hemodynamic instability | Hepatic encephalopathy | Infections | Metabolic disturbances | NAC | Nutritional deficiency | Renal failure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Monitor ICP, CPP & cerebral oxygenation *Elevate head end to 30° *Monitor fluid status *3% NS *Avoid NGT and suction | *Platelet count & coagulation profile (12th hourly) *Inj. Vit. K *Cryoprecipitate | *Discontinue medications *Avoid nephrotoxic & hepatotoxic drugs | *Ranitidine | *Monitor CVP w/ central venous catheter | *Frequent monitoring of mental status | *CBC (12th hourly) *CXR; sputum, blood & urine cultures (daily) *Cefotaxime, meropenem, fluconazole or vancomycin | *Serum BCH, ABG, lactate (12th hourly) *Serum glucose (2nd hourly) | *NAC (i.v × 2d then P.O.) | *Eternal feeding *Parental feeding | *Urinary I/O | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Etiology Specific Management
Etiology specific management | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
H/o acetaminophen intake Consider if no H/o but elevated aminotransferase (>3500 IU/L) | Jaundice, coagulopathy, thrombocytopenia ± hypoglycemia Hypertension & proteinuria + Steatosis during liver imaging or biopsy | Elevated aminotransferase responding to fluid resuscitation Associated renal dysfunction & muscle necrosis | + Serum autoantibodies + Liver biopsy | Abdominal pain, ascites and hepatomegaly + Liver imaging (CT/MRV/venogram/doppler USG) | H/o hepatotoxic drug intake (<6m) Unlikely if H/o intake >1 or 2 years | Massive hepatomegaly + Liver imaging & biopsy | H/o mushroom intake Suspect if no H/o but severe GI Sx (NVD) | + Hepatitis serology + Liver biopsy for HSV | Serum bilirubin >20g/dL, bilirubin:alkaline phosphatase >2.0, low serum ceruloplasmin, elevated serum & urine copper, + KF ring, + liver biopsy | Etiology undetermined | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acetaminophen toxicity | Acute fatty liver of pregnancy/HELLP | Acute ischemic injury | Autoimmune | Budd-Chiari | Drug induced | Malignant infiltration | Mushroom poisoning | Viral | Wilson's disease | Intermediate etiology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Activated charcoal NAC | Deliver immediately | Manage the cause of ischemia | Prednisolone Transplantation | Transplantation | Discontinue all possible medications except essential drugs | Supportive Rx | Activated charcoal & gastric lavage Penicillin G or Silibinin Fluid resuscitation | Supportive Rx Lamivudine or adefovir Acyclovir | Dialysis or hemofiltration or plasmapheresis or plasma exchange Transplantation | Incomplete drug or toxin intake H/O Transjugular biopsy to R/O mailgnancy, Wilson's disease, autoimmune hepatitis or viral hepatitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Complication Specific Management
Complication specific management | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ascites | Cerebral edema & increased ICP | Coagulopathy | Hemodynamic instability | Hepatic encephalopathy | Metabolic disturbances | Renal failure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Therapeutic paracentesis w/ 25% albumin <3 mEq/Kg of Na daily Lasix & aldactone | ICP >25 mmHg | + Bleeding or prior to surgery | Colloid, dextrose in crystalloid (if hypoglycemic) & 1/2 NS w/ 75 mg/L HCO3 (if acidotic) Norepinephrine±vasopressin Hydrocortisone | Grade | Rx acidosis, alkalosis, hypophosphatemia, hypomagnesemia, hypokalemia or hypoglycemia accordingly | Continuous venovenous hemodialysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SpO2 | Platelet transfusion (if ≤50,000/mm2) FFP /+ rFVIIa (if INR≥1.5) | I | II | III/IV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
<80 | >80 | 2nd hourly monitoring in quiet environment in high dependency ward | ICU management Stat CT to R/O ICH Short acting BZD Lactulose | ICU management Intubation & mechanical ventilation Propofol Elevate head end to 30° Quiet environment monitoring for CVP, hemodynamic & renal parameters, serum electrolytes, acid base status & neurological status | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20% mannitol | No improvement | Hyperventillation | Worsening | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3% NS | Transfer to ICU | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduce core temperature to 32°-34° (monitor for arrhythmias) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thiopental 125 mg i.v bolus | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Improvement or refractory | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transplantation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||